Results of subgroup analysis indicated that camrelizumab plus chemotherapy was more cost-effective for patients with specific baseline characteristics, such as patients older than 65 years old, patients with ECOG performance status score equals to 1, patients with disease stage IIIB/IIIC and patients with PD-L1 tumor proportion score ≤ 1%. Here, CD274 is linked to neoplasm.